DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Zhu AX, Kang Y, Yen C, Finn R, Galle P, Llovet J. et al.
REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
J Clin Oncol 2018;
36 (suppl):abstr 4003
Access:
We do not assume any responsibility for the contents of the web pages of other providers.